<SEC-DOCUMENT>0001606498-19-000010.txt : 20190319
<SEC-HEADER>0001606498-19-000010.hdr.sgml : 20190319
<ACCEPTANCE-DATETIME>20190129170600
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001606498-19-000010
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Avanos Medical, Inc.
		CENTRAL INDEX KEY:			0001606498
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				464987888
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		5405 WINDWARD PARKWAY
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30004
		BUSINESS PHONE:		678-425-9273

	MAIL ADDRESS:	
		STREET 1:		5405 WINDWARD PARKWAY
		CITY:			ALPHARETTA
		STATE:			GA
		ZIP:			30004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Halyard Health, Inc.
		DATE OF NAME CHANGE:	20140424
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3e44c31266f84e798fb7015639a074ea"></a></div><div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="avanoslogo.jpg" alt="avanoslogo.jpg" style="height:36px;width:224px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avanos Medical, Inc.</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5405 Windward Parkway</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Suite 100 South</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alpharetta, GA 30004</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">January 11, 2019</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">VIA EMAIL AND REGULAR MAIL</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Jeanne Bennett</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities and Exchange Commission</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Division of Corporation Finance</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office of Electronics and Machinery</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100 F Street, NE</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Re:&#160;&#160;&#160;&#160;Avanos Medical, Inc.</font></div><div style="line-height:120%;padding-top:0px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Form 10-K for the Year Ended December 31, 2017</font></div><div style="line-height:120%;padding-top:0px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">filed February 27, 2018</font></div><div style="line-height:120%;padding-top:0px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Form 10-Q for the Quarterly Period Ended September 30, 2018</font></div><div style="line-height:120%;padding-top:0px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">filed November 6, 2018</font></div><div style="line-height:120%;padding-top:0px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">File No. 001-36440</font></div><div style="line-height:120%;padding-top:0px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dear Ms. Bennett:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This letter is in response to the December 7, 2018 letter from the staff (the &#8220;Staff&#8221;) of the Securities and Exchange Commission (the &#8220;Commission&#8221;). We appreciate the Commission allowing the Company an extension of time, until January 11, 2019, to respond to the letter.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For convenience, the Staff&#8217;s comments are copied below, followed by the Company&#8217;s response. Since Comment No. 1 and Comment No. 2 are related, the Company addresses both together.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Form 10-K for the Year Ended December 31, 2017</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Note 15. Business Segment Information, page 63</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Staff Comment No. 1:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We reference your Disclosure in Note 2 on page 44 that as a result of the divestiture of the S&amp;IP business the Medical Devices business is managed as one operating segment. The objective of requiring disclosures about segments of a public entity is to provide information about the different types of business activities in which a public entity engages and the different economic environments in which it operates. The footnote does not disclose different types of business activities in which the Company engages, but rather includes a measure for the same set of operations that is presented in the consolidated financial statements. Please explain to us how the presentation of a segment measure for an entity with one operating segment complies with the objective of ASC 280-10-10.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Staff Comment No. 2:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a related matter, it appears that your presentation of segment operating profit (loss) is a non-GAAP measure. In this regard, please tell us how you considered the prohibition against presenting a non-GAAP financial measure in the footnotes to the financial statements. Refer to Item 10(e)(ii)(C) of Regulation S-K. In future filings, the disclosures required by Item 10(e) of Regulation S-K should also be provided for the segment operating profit (loss) measures provided on page 25 of Management&#8217;s Discussion and Analysis.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Jeanne Bennett</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities and Exchange Commission</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page </font><font style="font-family:inherit;font-size:10pt;">2</font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Company Response:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company describes its business activities in the second paragraph of the current Business Segment Information footnote as follows:</font></div><div style="line-height:120%;padding-top:8px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Medical Devices segment provides a portfolio of innovative product offerings focused on pain management and respiratory and digestive health to improve patient outcomes and reduce the cost of care. These products include post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems and enteral feeding tubes.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tabular presentation of net sales, segment operating profit, depreciation and amortization and capital expenditures was intended to help users of the Company&#8217;s financial statements to assess the Company&#8217;s prospects for future cash flows and make informed judgments on the Company as a whole. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the divestiture, the Company had two reportable business segments: the Medical Devices and Surgical and Infection Prevention segments. Each reportable business segment was reported along with &#8220;Corporate and Other&#8221; which, by itself, was not a reportable segment. &#8220;Corporate and Other&#8221; represents primarily general and administrative expenses. Following the divestiture, the Company&#8217;s senior management structure, including its Chief Operating Decision Maker (&#8220;CODM&#8221;), who is the Chief Executive Officer, has not materially changed, nor are significant changes expected in the near term. Likewise, the operating and financial reports that are reviewed and used by the CODM to make decisions have also remained consistent following the divestiture. Accordingly, the Company believes that the segment presentation of Medical Devices as its one operating and reportable business segment appropriately reflects the &#8220;management approach&#8221; described in ASC 280-10-05-03, which states that the information presented should be based on the way an entity organizes the segments for operating decisions and for assessing performance. Further, the management approach facilitates consistent descriptions in its annual report and other published information, as required by ASC 280-10-05-04.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Considering that the Company&#8217;s Medical Device segment reporting disclosures was determined in accordance with ASC 280, and considering the CODM and internal financial reports reviewed and used by the CODM to make decisions have remained consistent following the divestiture, the Company respectfully submits to the Commission that the presentation of segment operating profit (loss) is not a non-GAAP measure, and therefore does not require a reconciliation to the most directly comparable GAAP measure as described in Regulation G or Item 10(e) of Regulation S-K.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company acknowledges that a description of the different economic environments in which the Company operates is not included in the current Business Segment Information footnote, but are included elsewhere in Part I of the Form 10-K. The Company also acknowledges that, going forward, the overall relevance of &#8220;Corporate and Other&#8221; will be decreasing as the Company reduces its overall general and administrative expenses. Accordingly, the Company proposes to no longer separate &#8220;Corporate and Other&#8221; from the Medical Device reportable segment operating profit in the footnotes to the consolidated financial statements and in the corresponding table in Management&#8217;s Discussion and Analysis. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In future filings, beginning with the Company&#8217;s Form 10-K for the Year Ended December 31, 2018, the Company will revise the footnote and management&#8217;s discussion and analysis to remove all references to segment operating profit and the related reconciliation. The Company will rename the footnote as &#8220;Business and Products Information&#8221; substantially similar to the example attached hereto in </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit A.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Form 10-Q for the Quarterly Period Ended September 30, 2018</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibits 32(a) and (b), page 39</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Staff Comment No. 3:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We note that the 906 certifications in Exhibit 32 incorrectly identify the Form 10-Q filed August 7, 2018. Please file a full amendment to your Form 10-Q to provide revised 906 certifications that correctly refer to your Form 10-Q filed November 6, 2018.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Company Response:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 17, 2018, the Company filed an amended Form 10-Q for the Quarterly Period Ended September 30, 2018 with revised 906 certifications in Exhibits 32(a) and (b) that identify the Form 10-Q filed on November 6, 2018.</font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ms. Jeanne Bennett</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities and Exchange Commission</font></div><div style="line-height:120%;padding-top:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page </font><font style="font-family:inherit;font-size:10pt;">3</font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If you have any further questions or comments regarding the Company&#8217;s response to the Staff&#8217;s comments, please contact me at (470) 448-5200 or via email at steven.voskuil@avanos.com.</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:51%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avanos Medical, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Steven E. Voskuil</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Steven E. Voskuil</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cc:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">John W. Wesley, Senior Vice President and General Counsel, Avanos Medical, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Renato Negro, Vice President and Controller, Avanos Medical, Inc.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="secd3d31b903f49ffafdeaf7a55eb0949"></a></div><div><div style="line-height:120%;padding-top:8px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-top:0px;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;padding-top:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Introduction</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following proposed footnote disclosure replaces the former &#8220;Business Segment Information&#8221; footnote and reflects the following changes:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifies the business conducted as one operating and reportable business segment.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expands the description of business activities and the economic environments in which it operates using disclosures that were formerly included elsewhere in the footnotes to the consolidated financial statements or in Part I to the Form 10-K and in subsequent filings on Form 10-Q.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Removes the tabular presentation of segment operating profit and other measures.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incorporates certain disclosures now required under ASC 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Note __.&#160;&#160;&#160;&#160;Business and Products Information</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conduct our business in one operating and reportable segment that provides our medical device products to healthcare providers and patients in more than 90 countries with manufacturing facilities in the United States, Mexico, France, Germany and Tunisia. </font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We provide a portfolio of innovative product offerings focused on pain management and respiratory and digestive health to improve patient outcomes and reduce the cost of care. Our management evaluates net sales by product category within our single reportable segment as follows (in millions):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chronic care</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">325.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pain management</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">250.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Net Sales</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">611.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">566.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Chronic care </font><font style="font-family:inherit;font-size:10pt;">is focused on (i) digestive health products such as our Mic-Key enteral feeding tubes and Corpak patient feeding solutions and (ii) respiratory health products such as our Ballard closed airway suction systems and oral care kits.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Pain management </font><font style="font-family:inherit;font-size:10pt;">is focused on non-opioid solutions including (i) acute pain products such as On-Q surgical pain pumps and (ii) interventional pain solutions, which provides minimally invasive pain relieving therapies, such as our Coolief pain therapy.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended December 31, 2018, 2017 and 2016, products in our acute pain, interventional pain, digestive health and respiratory health categories each accounted for more than 10% of our consolidated net sales. For the years ended December 31, 2018, 2017 and 2016, net sales to external customers in the United States were $___ million, $467 million and $410 million, respectively.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net sales to one customer accounted for __%, 10% and 9% of consolidated net sales in the years ended December 31, 2018, 2017 and 2016, respectively. No other customer accounted for more than 10% of consolidated net sales in any of the periods presented herein.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Due to the nature of our business, we receive purchase orders for products under supply agreements which are normally fulfilled within three to four weeks. Our performance obligations under purchase orders are satisfied and revenue is recognized at a point in time, which is upon shipment or upon delivery of our products, depending on shipping terms. Accordingly, we normally do not have transactions that give rise to material unfulfilled performance obligations.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, plant and equipment held domestically and in foreign countries is as follows (in millions):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Domestic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Property, Plant and Equipment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">109.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>avanoslogo.jpg
<TEXT>
begin 644 avanoslogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_[@ .061O8F4 9      !_^$ AD5X:68
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M 1$  A$! Q$!_\0 'P   @(" P$! 0            H)"P<( P0%!@(!_\0
M6!    8! P(# P0)#0L- 0   0(#! 4&!P 1"!()(1,*,4$442(5%S)"M-26
M5W=X.6%QL7*2LB,S);75%EA2<[,D='6V-Q@X&H'!8H)#4\/C-(0UAD@9_\0
M&0$  P$! 0                ,$ @$%_\0 )!$  @,  @(# 0$! 0$
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MQGJQ9H9?X:5A)ABAU).$%-AZ#IF\0';6;^$S5/+17>?_ -;>Y5_;/SE^%/\
MY6H/Z6^RKHOH>9[%^:<KY_[=^.\EYIOUCR5?92\Y38/[7:GOTA,.F43-.$&R
M1U1 HB5%(H%( ^P/#5F-G:ODFT4/P3 ::8#0 : (%.Y-WZ>/?":2G,38HCVG
M(/D/%F58RT!%2P-,=X[DB@("G.RJ(*'7<HFVZX]F G#Q*JJ@8  4Z;*GA<C:
M9.PG_P DN\CW$.3SU]_6SD-:Z#67:@F2HN%W2N+JPT1$!#R1/&JDDWA! =A!
MX\5W]^I;:VM\CUFD1O2]LM5A>'D9^S6"<D%#"91_+S+F2>*&-XB)E5E#G$1_
M5'2YDU!F#%G*[DWA"1:2F(N0&8,>.62J:R256R%*1<<J*?B!5V9'/PCDGRIK
M)&*/O#759KAG'5,8-X1>IDSSCF2AZ=S1K+7.%",HV9N<E5&-:UG+,&@8P =P
MNU2^&AYHJ9!W\H$VZ@[;^:8?#3Z>PUR+MBGP.:<?.1.&>4V+J_F3!%[AL@4"
MQIF!M*Q2HE<QT@B!1782#50".8]VV$P LV<$*<NX#MTB41KK964HG:Z\F:]=
M.!H - $&7=C[U6-^WNDIB7',/%Y8Y12L8@_2JCUX=*G8TCI%/K;/[$HW,5PJ
MHL42J-XU$Y%%"#UG41()!43KKT\?(RF?<25Y&]SOG7RGEG[[*_([(HP[U9<Z
M5&I<XM0: Q;K#N"!(F).U;KE3#P*=R"BFWM.([CJ2VCMRRA4532%.P3Z3SZ1
M2FY=*0\SS?CDY)8CSS?;U>:!P/OO[]]8-&Z. NY?SLXT2K.0Q1R;RFR8M%$!
M&J6BR+7RD.44# 84CP\T+Y@0IP#I,9),I]O88!V$-UT=>&<=$_@<M[//>QG>
MX':G. \N8<>5W,\!4WMJ<Y QTU5>8KFH6(%%)9600<*J.J^NJLL0B1!5625,
M.Q3ICTD&K+7OX9/IGU\C"^GB@T *%>J2Y9 PKN$N&-:DT_B)]T;-N4&S=4AU
M$XR+,O'UQHMT'ZR LY%ZY.D<NP^6B</8&I?8M\#\:_(F1J4H,A8ER9:,,90Q
M[ENE/5H^VXUN5=NU>=H+&;G3E:VZ2=I )R^(%.9+I-\H"(:ZG'DXU);&8 S)
M6.0V$<4YQIJQ5JUE6AUJ[Q8!U=34D\U364;' Y2F [58QT5 $ $#%$->E5]E
M)$U#@R]KIP- "O\ ZGOBP.0^-.,^4<!&F<6' EK-5[:X;IJ*+#CC(YTDBJ*
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M RK&2<;-1S"8AY!C+1,HS;2$9*1CM-_'2+!X0%$5T%TC'26353,!B'(80$!
M0';5 D[V@"OX]25RO/FSFLQP/!2BKFD\8*V2MN6J2RGP*N3+@1"0FEN@1\LQ
MV[8&30Q@#P,D<N_MU%O:7'T595A21F]LGBTXYB\WL"X259KNJJ_MS>U9&41
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MS5JA>DF'4=1$IA\T6,H4IG#%0WM+U)B(J)*;6]^]6R;KTLBOEU"5%B[Z<_\
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M9OQ:U<+F.(LW!D8ZR-$2B7I(5)86#DI0-N(J*FV\!'5/KVY0C:OR.$ZJ$!H
M7:]3=^CN@OSA,>_<$UI'L?D;CR5_&HBHME^&7^Z'Q=_-\P]_H_'Z]*G"(;<F
M=;95*W>JQ8:5<82.LE3MD+)URRU^7;%>1<U!S*)V[IJX2-\U1-=%0Q# /N'6
MFI.%:IW=>VQ9>W=R*=Q,,TE)/CWDY>2L6$K@Z 7)4F!% ,[KSU?;87L(*I""
M)O%5$R2H>)CE)Y^N?1_\*\[]D:*83Y&9/P&RRU#4*8\BN9PQ99L0Y,K;SJ7A
MK)5+&D(%,HB!@*#A@OTKM%P^<0W4 #TG.4V:V=3;4F"=9.EB[Z<_]%OBO\HF
M9/Y_=ZNP_))K^B<_3A9@+E/@R)Y,<<<UX"FE"H,LKXXL].2=F$ ".E))L<&+
MK<2*;?"/2I+ /2(_-\/'6;+LH.IPY*G_ "#0[5BZ]7'&UXB74#<:'99JHVB&
M>HG0<QL[7W"C5RD8JA2'#I52-L(@&X;#[]><U!:G(SGZ;KN,UW#=UL'"/,%@
M1A:?EZQDL^%9Z5< C%Q&4W::35U"*JJ& J!9]%%$6N_A\0GY8?/<!JC#2/#$
MZTGR/%:K)PT &@#2SGSS9QCP*XY7'..0W[165;M',/C2EBY!.6R'D)VD<6$:
MU3WZQ(!P\UVJ ;)(E.<?$  <7NJ*35:]G!5N9*R':\MY#N^4;U)'E[ED.USU
MSL\D?< =SEC<J.W)B%$QN@GFJB!" .Q2[%#P ->>W/DL2@:O]+=Q0DY"\9KY
MEV*+61@:]!CA3&CQPB<B,E8)P[:0L#A#K3 IO@6B#-N"A##XK*$';80&CUZ_
M(G:WP.CZK)PT >02P0*DZO5TYN(/9FT4WG7-=))(FG6\([5402>': ?X@B"J
MZ*B9%1)TB8IB@.X"&@#U] !H 0#]25Q/Q7Q[Y9X^R5BN&C*HWY%TV?MERJD,
MV(RBT+S6GR;=[*(MT]B(?2R;M(ZI2% IE2**;=1S#J+>JJY15E:40 8ZM,K1
ML@T6ZP2RK:;I]RK%IAG"!A(LA*U]Z@[;G((>(&*LB40$/?I"<#.1TKU0_+ U
M0PUB/B'6Y$R,QEJ<')N0DFZAB*%HE+.9&,:J]"@ )'\P<5NDY1\6H"&J_8M"
M@GQK\B0FI"D<1X@>H7X2<2.,^&>.]7X[<B73/&-'B(63E"!6$_IRTK%^)F'_
M (2Z8B#R47<*D$Q0'I$H" "&P55W55$$]LG9R;(_\5+Q(_LY<C/W=9_IK7?]
M*^CG\6'_ !4O$C^SER,_=UG^FM'^E?0?Q8MIW=.:_'WGYR'KW(+"6.,B8WFW
MU$CJKDUI?/HP0L$K6E#)QC]L,<\>;G"..5LMY@E^:DETA]D.D:W5W*&YU=5#
M-$>..;;+QNSUB+/%044+/XIOU<N;1%,2%^D&\0X(=TS,)RG)T/FGFMU-P'YI
MQUBKZN3;4J"V)QAD2L9=QQ0\ITJ01E:CD:H5V[5J1;J JB\A+,T2>-C@8-@'
M=)8-_P!77I)R1-0?=:Z<#0 DGZH_BT:M9;PMRY@& %BLEP"V*;\NB4VR5OI@
M&<Q*ZO2F! %[%K*(@8Q]Q^' -M@U)[%8<E&-O@4_U,//VDDHLHFBBF=594Y$
MDDDB"HHJHH.Q2E*&XF$PCL !H M'>U;Q>#B%P1P%B)\S*RMRE41OF0R=)RK?
MU]R!M)OTE04*0X&9>>1IL(> )  > !KT<Z]:I$=WV9(9K9@- "8GJD^6(25F
MPCPSK4EU-ZVU4S7E%NV7'I&7ERK1]=9K 0^W4@T!ZZ.F<OL51.'NU)[%O@HQ
MK\BB: (BLB#DZJ;<54P<'03!58B(B'6)"F,0IC 7?8!, "/O#4P\=5P[ZE/@
M]@_$^-\.T?C/R,8U'&%(K-&K[;JK'66,K+-)HF8XA,AUG4!+K4/MN8PB8?$=
M5KV$E$$SR;,D?\5+Q(_LY<C/W=9_IK1_I7T'\6'_ !4O$C^SER,_=UG^FM'^
ME?0?Q8K)W.^3F#>8_+6X<C<$T:\8[B,C0U<>72O7HK$'RM]BVX,G;UN+!Z]1
M\IXV;MSF 3%'S.LVWSM3Z65W*'43JH9\#V^^3;[A]S%P-G]!9P2(IEX8-[JU
M;J@D,ECZQ@:-G&X]7S!$T8Z6,GU ( <"F]I0T4MT<G;+LH+52*E(Z<C(Z:AW
MK:2B9=@SE(N19*@X9R$=()E50724*(E.15(Y3%,'@(" Z]$B._H 7:]3=^CN
M@OSA,>_<$UI'L?D;CR5_&HBHME^&7^Z'Q=_-\P]_H_'Z]*G"(;<FRNM'#4+G
M)PUQCSLXZW3 636Y6Z<RW&4I=M00*M+4"^1Z:GT=+M-]A$4%#B1=+< 51,HD
M(@!]PS>BNH9JMNKDK .2''C*'%3-5]P-F&!5@;SC^:7BWQ-A/'S# ?GLY-@J
M( #AI(MC$7;JA[2&#< ,!BAYUJ]7#+$^WDP?KATL7?3G_HM\5_E$S)_/[O5V
M'Y)-?T3GZ<+#0 GKZB3M4S4W(2_< X_UL\D<D<W#DM38-CU/2H1*144;DW01
M+NJ5-LF5*6V 1*4I'([E\\Y9=\__ *0_*_PQ.!)51%1-9%0Z2R1R*I*I'%-1
M)1,=RF*8-A*)1#<!#4I0,\=OOU)&6L$UZ#Q5S!JDSGZBPK=".A<H04@DWS%"
MQR =*:4@5X8C.Q%3* %*JJLBN ;B=58=@"C/?KX8FV4\$_%:]0UVN+!&?2#K
M,MNJS@J(*JQ%DQ1/)221A#?HW9LWK90P>S^#6,'ZNGK>HK^5C4?DEZGSB;1X
M-ZTXTX\R!G.YJME C)"SQQL:8^8N1$"E.Y4=>9,. * B;RDV9.K;I\PF^X8M
M["7!I8M\B?/,?FYR&YV925RKR"N1YV0:HK,*I58I(T71Z%"K& PLH:.ZU"-B
M'$I155.8ZJH@!E5#B "$M[N[ECZU5> X5<,LQ\Z\[UC!F'8@ZSR262?6^W.V
MZAJUCJFHJ$*\F)18@"!$T"FV23 >M902I)@)S!HI1W<(+6ZJ2SWXM<;<<<1L
M"XXX^8JCP9U''<$E&INU$2)2-AF5S&6D)5Z) V.YDWJBCA8?8 FZ2[% H!Z%
M:]5"(V^SDV UHX1I]SON48Q[;V$2W2PMDK;EJ\%E8G"^,"JF1-:9Z/(F*SQ^
MJ3YS6-BQ72.[5 >HW45)/YYP$J]-/YHW2G=E>VS[BW,..Y92/-=CF6P-L_2T
MFHYDI\@E/!O8%02@$ K%'ZF*D0FBF1%./,04RE*42@"A2G"+^CF?DJZ*(&KN
M*7J@\!VR$C87EYC&U8FN:#4J<E<\:L#WC'4JY2 H&6*Q%7Z;C?-$1,"(%<@7
M_O1U37V$^1%L7\&[5\]1'VQ*A6',["92NF198K)9PPJ-0QE,(34@Y(03$0%6
M5;QK!L)S;%ZEER@'MUI[U1E9,27[D7/F]]Q/D=*9LM<02HUF+B6].QE04'YI
M%"H4J.5663(LL($(X=O%UU%W:Q2% 3"!"AT$( 2:7_HY**5Z*#I=M#BY8.7_
M #7P1A^(CU7D(-SB+ID5V"(JM8C&M*<HOI=9<0\$P713!HD8?#S54P\=]M&=
M>S2"[ZHSAW4[_FOF7SGSCF&/Q?E)]26M@-C[&!BT*4.W#'E"$[!BLB(,B#T2
M*A%G^Q@W 5A ?'7=6[6;.475$>'U'YJ_%!E'\ );[TUB#<A]1^:OQ091_ "6
M^]-$!(?4?FK\4&4?P EOO31 2'U'YJ_%!E'\ );[TT0$A]1^:OQ091_ "6^]
M-$!(?4?FK\4&4?P EOO31 2/I>G.SK>+OPODL!Y/KUN@+=QMM2D%!&MD$[AE
M)/&=T%>1B@0,[(F9?Z/=E>MC%*&R:94 ^V#5N%I4$VJ\C!6G"@T 1N=VSBN/
M+_@3G;%T9'#)7>$KXY.QFBDF99V>^8\ []LW;E*("962:E<,"[^'\/XZ7K7M
M5HW1]65HWU'YI'Q#$&4!_P#H$M]Z:@AE<DD?:3X)Y!Y$<]L$U6_XRN,3C:GV
M ,JY#=6:IOHJ'7K./!(^*R54<HHD,$G(%:LA*4V^RHB ; .V\J=K&+VA%ESK
MT"0- 'ESDS'5R%E[#+KF;1,%%R$S*.2(*.CMXZ+2.NN<$DBG54$B1#"!2%$P
M^P $?#0!5K\TK#R Y=\I<V\BI;$V55"9,O$G+0""E%F%PC::SZ6D(S(8S,#=
M+2);MTB[A]KKSKMV<EM5U4&K_P!1^:OQ091_ "6^]-9@[(?4?FK\4&4?P EO
MO31 2'U'YJ_%!E'\ );[TT0$A]1^:OQ091_ "6^]-$!(?4?FK\4&4?P EOO3
M1 2'U'YJ_%!E'\ );[TT0$EBCV,.0-NS=P$QW6LDQ5GA\D8"74PM8T+9$/HJ
M2?0U<115@78"^3(=<IX5=NB)RB(=29@]H:NQMVJ2Z*&3%Z:+%]?4GUJQVKM^
M0<95Z_.622#/V/W Q\!$N)EZ5 C&9 R@I-DU#@4!, "80VW$ ]^D>Q^1N7(A
M:.$,T@ B.(<H   (B(T"6   /_::C@IDM3N'C5TQXF<963ULX9/&F \1MG;-
MX@=JZ:N4(%@4Z:B:@%.F8A@$#%, " ^ Z]&G"(K<FQVM' T 0/=\GM;-><V%
M!R]B:"3-RDPK#/'-9(T J+C*5%0ZW#RMK^SS7"9NIQ%G,/@J)T? JXF(G;/N
MI7(W._40&-@W-A#&(?#V4BG(8Q#D-CZ6*8AR#L(" M-P$!#80U%!3)80^GJ@
M9VM=L?&$38X27K\JAD++ZBT9.1B\2_336G71B&%%P1-0 .4=P';8=6X**DNO
M)-SIPL- '&LBDX2507237073.BLBL0%$EDE $IBF*8! P& =A ?;H 5'[EWI
MPZ[E*8L&:>"+NO8\M\HLO*V' 4\J$1CZ:?JB8ZJM<>E*8D&HL8=P9+%^&W$>
MA1N0 (,VF$^:CJ:QX8H?GGBGR0XP3RU<S]A;(6+)!)Q\*DO:*\LW@Y%7;?\
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E\# _Y\;?X74M.2E\%F'@G_5/2?\ ,;#_  1->@B-\F7-=.'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
